Literature DB >> 33665735

Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis.

Mohammed El-Gedamy1, Zakaria El-Khayat2, Hassan Abol-Enein3, Afaf El-Said4, Eslam El-Nahrery5.   

Abstract

Bladder cancer (BLC) is a recurrent high-risk malignancy typified by an inherent localised chronic inflammation. IL-23-receptor (IL-23R), as a positive regulator in the priming of T helper-17 cells, is regarded a principal coordinator of inflammation-propelled neoplasia. In this article, we indented firstly to scrutinise the influence of rs10889677"A/C" SNP located in IL-23R-gene on BLC development and progression among Egyptians. Findings revealed that the rs10889677"C" allele was significantly associated with the increased BLC risk and its higher frequencies were plainly noticeable in high-grade and invasive tumours when applied the dominant/homozygous/allelic genetic models. Under the same genetic models, elevated serum levels of IL-23R protein in BLC patients were pertinently correlated with the rs10889677"A/C" polymorphism. As a corollary, the frequent up-regulation of IL-23R exerts a subsequent activation of the IL-23/17 inflammatory axis. That is experienced as a drastic increase in IL-23 and IL17 levels under the dominant/homozygous/heterozygous/recessive models. Second, study further described how the rs10889677 variant confers its pro-tumoural influences on IL-23R-bearing immune cells, involving tumour-associated macrophages (TAMs), natural killers (NKs) and CD4+ T-helper cells. When the dominant model was adopted, it was observed that patients bearing the rs10889677 "C" allele had lower counts of IL-23R-positive CD56+NKs and CD4+ T-cells, in tandem with higher levels of IL-23R-positive CD14+ TAMs compared with those with rs10889677 "A" allele. To entrench the idea, we did a meta-analysis on BLC patients from three different ethnicities (Asian, Caucasians and African). We observed that rs10889677"SNP" is significantly correlated with increased risk of BLCs in the overall population using over-dominant model. Consequently, authors suggested that the rs10889677 variant could be directly implicated in developing inflammatory environment more prone to generating malignancy.

Entities:  

Keywords:  Bladder urothelial carcinoma; Gene polymorphism; Interleukin 17; Interleukin 23; Interleukin-23 receptor; Natural killers; Tumour-associated macrophages

Year:  2021        PMID: 33665735     DOI: 10.1007/s00251-021-01205-w

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  87 in total

1.  Injury induces in vivo expression of platelet-derived growth factor (PDGF) and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in connective tissue fibroblasts.

Authors:  H N Antoniades; T Galanopoulos; J Neville-Golden; C P Kiritsy; S E Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

Review 2.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

3.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

4.  Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.

Authors:  Esra A Akbay; Shohei Koyama; Yan Liu; Ruben Dries; Lauren E Bufe; Michael Silkes; Md Maksudul Alam; Dillon M Magee; Robert Jones; Masahisa Jinushi; Meghana Kulkarni; Julian Carretero; Xiaoen Wang; Tiquella Warner-Hatten; Jillian D Cavanaugh; Akio Osa; Atsushi Kumanogoh; Gordon J Freeman; Mark M Awad; David C Christiani; Raphael Bueno; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  J Thorac Oncol       Date:  2017-05-06       Impact factor: 15.609

Review 5.  Bacteria as vectors for gene therapy of cancer.

Authors:  Chwanrow K Baban; Michelle Cronin; Deirdre O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 6.  Role of bacteria in oncogenesis.

Authors:  Alicia H Chang; Julie Parsonnet
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells.

Authors:  Maria Laura Belladonna; Jean-Christophe Renauld; Roberta Bianchi; Carmine Vacca; Francesca Fallarino; Ciriana Orabona; Maria Cristina Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

Review 8.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Authors:  Sebastien Antoni; Jacques Ferlay; Isabelle Soerjomataram; Ariana Znaor; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

9.  Developmental aspects of sugar transport by isolated dog renal cortical tubules.

Authors:  J W Foreman; M S Medow; H Wald; K Ginkinger; S Segal
Journal:  Pediatr Res       Date:  1984-08       Impact factor: 3.756

10.  Soluble CD44 and CD44v6 and prognosis in children with B-cell acute lymphoblastic leukemia.

Authors:  Zahra Amirghofran; Elham Asiaee; Fatemeh M Kamazani
Journal:  Asia Pac J Clin Oncol       Date:  2014-09-16       Impact factor: 2.601

View more
  1 in total

1.  Cytokine-driven positive feedback loop organizes fibroblast transformation and facilitates gastric cancer progression.

Authors:  Xian-Kui Cao; Bin Xie; Yang Shao; Jie Lin
Journal:  Clin Transl Oncol       Date:  2022-03-18       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.